Amyloid peptide (Ah) is a 40/42-residue proteolytic fragment of a precursor protein (APP), implicated in the pathogenesis of Alzheimer's disease. The hypothesis that interactions between Ah aggregates and neuronal membranes play an important role in toxicity has gained some acceptance. Previously, we showed that the C-terminal domain (e.g. amino acids 29 -42) of Ah induces membrane permeabilisation and fusion, an effect which is related to the appearance of non-bilayer structures. Conformational studies showed that this peptide has properties similar to those of the fusion peptide of viral proteins i.e. a tilted penetration into membranes. Since piracetam interacts with lipids and has beneficial effects on several symptoms of Alzheimer's disease, we investigated in model membranes the ability of piracetam to hinder the destabilising effect of the Ah 29 -42 peptide. Using fluorescence studies and 31 P and 2 H NMR spectroscopy, we have shown that piracetam was able to significantly decrease the fusogenic and destabilising effect of Ah 29 -42, in a concentration-dependent manner. While the peptide induced lipid disorganisation and subsequent negative curvature at the membrane -water interface, the conformational analysis showed that piracetam, when preincubated with lipids, coats the phospholipid headgroups. Calculations suggest that this prevents appearance of the peptide-induced curvature. In addition, insertion of molecules with an inverted cone shape, like piracetam, into the outer membrane leaflet should make the formation of such structures energetically less favourable and therefore decrease the likelihood of membrane fusion. D
Introduction
Alzheimer's disease is a progressive degenerative disease of the brain characterized by loss of cognitive function (dementia), selective neuronal death and abnormal formation in the brain of neuritic amyloid plaques. Genetic, neuropathologic, transgenic and modelling studies implicate the accumulation of h-amyloid peptides (Ah) as an important step in the pathogenesis of the disease [1, 2] . Ah is a 40/ 42-residue proteolytic fragment of amyloid precursor protein (APP), an ubiquitous transmembrane protein [3] . Under pathological conditions, Ah polymerises into extended hsheet structures that result in Ah fibrils characteristic of the amyloid plaque.
The mechanism leading to Ah toxicity has been extensively debated [4, 5] . The hypothesis that interactions between Ah aggregates and neuronal membranes play an important role in toxicity is now generally accepted [6] . In vivo studies have shown that Ah proteins aggregate in a membrane-bound conformation in dog and human brain sections [7, 8] and induce free-radical oxidative stress of neuronal lipids in brain of Alzheimer patients [9] . In cellular models, Ah has been reported to alter intramembranous structures [10] , to increase permeability in lysosomal and endosomal vesicles [11] , to induce the formation of cation-permeable channels [12] and to enhance the activity of phospholipases A 2 , C and D [13 -16] . In addition to these in vivo and cellular observations, numer-ous studies have been performed using models of membrane to characterise at the molecular level the binding of Ah fragments to lipids [17 -19] , and the effects of this interaction on the biophysical properties of the membrane. In this respect, Ah peptides induce liposome fusion [20] , leakage of encapsulated dyes [17] , formation of ion-channels [21, 22] and perturbations in membrane fluidity [23 -27] .
Focusing on membrane destabilisation and on the Cterminal domain of Ah (residues 29 -40 and 29 -42) which is critical for amyloid aggregation and fibril stabilisation [28, 29] , Brasseur [30] has related membrane destabilisation to the ability of the Ah C-terminal fragment to penetrate into membranes with a 30 -60j tilt with respect to the plane of the lipid/water interface.
A number of approaches have been investigated to improve the daily living activities of patients presenting Alzheimer's disease. For example, Ginkgo biloba, tacrine, donezepil (acetylcholinesterase inhibitors), nimodipine (calcium channel blocker) and piracetam (nootropic agent) have been approved for the treatment of demented patients in some European countries [31] . Clinical insights into nootroopic agents have shown that (i) long-term and high dose treatment with piracetam may slow down the progression of several clinical features of Alzheimer's disease [32] , (ii) they have a comparable efficacy to acetylcholinesterase inhibitors [33] and (iii) the cognitive relapse after discontinuation of the drug therapy is less pronounced compared to cholinesterases inhibitors [34] . However, the molecular mechanism of piracetam's beneficial effects in Alzheimer's disease is not yet understood. Since results from the literature suggest that piracetam interacts with lipids [24] , we have investigated in model membrane systems the ability of piracetam to hinder the membrane destabilising effect of the Ah 29-42 synthetic peptide.
Materials and methods

Preparation of small unilamellar vesicles (SUV liposomes)
These studies were performed on SUV, made of phosphatidylcholine (PC)/phosphatidylethanolamine (PE)/phosphatidylinositol (PI)/phosphatidylserine (PS)/sphingomyelin (SM)/cholesterol (Chol) (30%:30%:2.5%:10%:5%:22.5%) to mimic to some extent the composition of the neuronal membrane [35] .
A dry lipid film was obtained by evaporation of the solvents of lipids (CHCl 3 /CH 3 OH: 2:1) in a rotavapor. After overnight dessication, liposomes were prepared by 1-h hydration of the dry lipidic film with Tris buffer pH 8 (Tris 10 mM, NaCl 150 mM, EDTA 0.1 mM, NaN 3 1 mM) at 37 jC in a nitrogen atmosphere. The suspension was sonicated at 4 jC under a stream of nitrogen with a Braun Labsonic-L sonotrode (Braun Biotech International, Melsungen, Germany) set at 50 W for 5 Â 2 min with 1-min cooling intervals until the opaque suspension became translucent. The preparations were then centrifuged at 1000 rpm for 10 min (Damon IEC -CRU-5000) to remove particulate matter. The actual phospholipid concentration of each preparation was determined by phosphorus assay [36] . Total lipid concentration was calculated assuming a similar recovery of phospholipids and cholesterol. Liposomes were used the day following their preparation.
Fluorescence and light scattering studies
Fusion of lipidic phase
The fusion of lipidic phases was determined by measuring the dequenching of the fluorescence of octadecylrhodamine B chloride (R 18 ) [37] . The fluorescence of this lipid-soluble probe is self-quenched in proportion with its membranous concentration and any decrease of its surface density is therefore associated with a commensurate increase of the fluorescence intensity of the preparation [37] . Labeled liposomes were obtained by incorporating R 18 in the dry lipid film at a molar ratio of 5.7% with respect to the total lipids and diluted to a concentration of 5 AM in total lipids. These labeled liposomes were mixed with unlabeled liposomes (adjusted to the same concentration) at a ratio of 1:4. Peptide (or piracetam) were added and the fluorescence was thereafter followed at room temperature during 25 min, using k exc of 560 nm and k em of 590 nm (Perkin-Elmer LS-30, PerkinElmer Ltd, Beaconsfield, UK). Additional experiments were performed where liposomes were either preincubated 20 min with piracetam before the addition of peptides or with peptides during 20 min prior addition of the drug. Results were expressed as fluorescence values calculated as the difference between the fluorescence signal recorded for the mixing of labeled and unlabeled liposomes and that recorded in identical experimental conditions for the labeled liposomes mixed with peptide or piracetam. This correction was made to rule out any interference of the peptide or piracetam on the fluorescence of the marker.
Fusion of aqueous phase
Two preparations of labeled liposomes were used. The first population of liposomes contained hydroxypyrene-1,3,6-trisulfonic acid (HPTS; 1 mM) and the second pxylene-bis-pyridinium bromide (DPX; 50 mM) dissolved in Tris buffer pH 8 (Tris 10 mM, NaCl 150 mM, EDTA 0.1 mM, NaN 3 1 mM). The mixture of aqueous phases of the two populations of liposomes was monitored by the decrease of HPTS fluorescence due to the quenching of HPTS fluorescence by DPX. After liposome preparations, the unentrapped probes were eliminated by minicolumn centrifugation. The two types of liposomes were diluted with Tris buffer pH 8 at 50 AM and mixed at a ratio of 1:1. Peptide (or piracetam) was added to the liposomes and the fluorescence was thereafter followed at room temperature during 25 min. In some experiments, liposomes were preincubated 20 min with piracetam before the addition of peptide whereas in others, the drug was mixed to liposomes preincubated 20 min with peptide. Fluorescence of HPTS was monitored with a Perkin-Elmer LS30 fluorescence spectrophotometer (Perkin-Elmer) using k exc of 450 nm and k em of 512 nm.
Determination of the size of liposomes
The apparent average diameter of SUV was determined by quasi-elastic light scattering spectroscopy [38] using a CoulterR Nano Sizerk N 4 MD (Coulter Electronics Ltd, Luton, UK), as described earlier [39] . The liposomes concentration was set at 65 AM (total lipids).
Fluctuation of light scattering was measured at an angle of 90j with monodisperse latex particles of 100-and 800-nm diameters as control. Data were analyzed using size distribution analysis mode to determine the full size distribution profile of liposomes mixed with the h-amyloid peptide and/or piracetam. In some experiments, liposomes were preincubated 20 min with piracetam before the addition of peptide whereas in others the drug was mixed after incubation during 20 min of liposomes with peptide.
Permeability studies
As described by Weinstein et al. [40] , leakage of entrapped, self-quenched calcein from liposomes can be monitored by the fluorescence increase subsequent to its dilution. The dried lipid films were hydrated with a solution of purified calcein (16.3 mM) which had an osmolarity of 461 mOsm/kg [measured by the freezing point technique (Advanced Instruments, Needham Heights, MA)]. After preparation of the vesicles, the unencapsulated dye was eliminated by the minicolumn centrifugation technique [41] . The liposomes were diluted to a final lipid concentration of 5 AM in an isoosmotic 231 mM Tris buffer pH 8 (461 mOsm/kg), and then the peptide (or piracetam) was added at room temperature. Again, additional experiments were performed with liposomes preincubated 20 min with piracetam (or peptide) before the addition of peptide (or piracetam). The percentage of calcein released under the influence of peptide was defined as [( F t À F contr )/( F tot À F contr )] Â 100, where F t is the fluorescence signal measured at time t in the presence of the peptide, F contr is the fluorescence signal measured at the same time t for control liposomes, and F tot is the total fluorescence signal obtained after complete disruption of the liposomes by sonication (checked by quasi-elastic light spectroscopy). All fluorescence determinations were performed at room temperature on a Perkin Elmer LS 30 Fluorescence Spectrophotometer (Perkin-Elmer) using k exc of 472 nm and k em of 516 nm.
NMR studies
2.3.1.
31
P NMR Multilamellar vesicles (MLV) of the same composition as that used for fluorescence and light scattering studies were prepared as follows: organic solutions of the lipids were dried under vacuum, hydrated over 1 h at 37 jC in Tris buffer pH 8 at a concentration of 10 mM in phospholipids, maintained at 37 jC for a further hour and finally submitted to five freeze -thawing cycles. The same procedure was used for preparing DMPC/DHPC (dimyristoylphosphatidylcholine/dihexanoylphosphatidycholine in a molar ratio of 3:2) liposomes at a concentration of 20 mM in phospholipids.
Peptide-containing samples were prepared by the following procedure: peptides were first dissolved in trifluoroacetic acid [42] , the solvent removed with N 2 gas and the sample dried under vacuum. The peptide dissolved in DMSO (6 mg/ml) was simply added to the MLV suspension. Piracetam-containing samples were obtained by dissolving in the buffer the necessary amount of drug to reach a 200 mM final concentration in the sample. 31 P NMR spectra were obtained at 101.3 MHz with an AC 250 Bruker spectrometer. Two milliliters of MLV suspension were used in 10-mm NMR tubes. D 2 O (15%) was added for locking on the deuterium signal. Fourier transform conditions were: 25 kHz spectral width, 4 K data points, flip angle 40j (10 As), 1.2 s pulse interval. Five thousand scans were accumulated and a 50-Hz line broadening was applied to the free induction decay before Fourier transformation. Powergated 1 H decoupling was applied. Experiments were conducted as a function of temperature: samples were heated and cooled down with 30-min equilibration times between each accumulation at each new temperature.
2.3.2.
2 H NMR Aqueous solution of binary mixtures of long-and shortchain phosphatidylcholines may form a well-oriented nematic phase of bilayered discoidal mixed micelles called bicelles [43] . We used DMPC/DHPC in a molar ratio of 3.5:1. The DMPC solution in CHCl 3 (containing 25% of DMPC-d 54 ) was evaporated under vacuum, resuspended in 2 H-depleted water and vortexed, centrifuged and freezethawed for obtaining a homogeneous slurry. Stock solution of DHPC in 2 H-depleted water was added to the DMPC suspension. The final phospholipid content of 20% (w/w) was adjusted with 50 mM 2-morpholinoethane sulfonic acid monohydrate (MES) pH 6.
Peptide-containing samples were prepared by the same procedure as for 31 P NMR studies but the Ah 29 -42 in DMSO (see supra) was added to a CHCl 3 solution of DMPC. The solvents were evaporated under vacuum, the dry peptide -DMPC mixture was resuspended in 2 Hdepleted water and this suspension was treated as control samples (see above) before addition of DHPC solution and buffer. During this study, severe difficulties appeared in the bicelle preparation: the samples were highly viscous but not completely transparent. After centrifugation, the suspension became more transparent but a pellet was observed, indicating that the peptide was not well inserted in the bicelles. For improving this incorporation, we decided to perform the 2 H NMR study with a less hydrophobic fragment of Ah, the 22 -42 peptide. This fragment, which also induces significant lipid fusion [20] , is much less hydrophobic than the Ah 29 -42 as indicated by the calculated grand average of hydrophobicity (GRAVY index; [44] ) (1.07 vs. 2.41) or by the normalised consensus hydrophobicity scale of Eisenberg et al. [45] (0.47 vs. 0.89). We decided to synthesise this fragment with a Tyr residue at the N-terminus (GRAVY index of 0.96) to allow the peptide purification by HPLC.
The incorporation of Tyr-22-42 in bicelle solutions was satisfactory. The longer peptide-containing samples were transparent and highly viscous after addition in DHPC solution.
The preparation of piracetam-containing samples was similar to that of control bicelles, but the drug was dissolved in the 2 H-depleted water employed for resuspending DMPC or DMPC -peptide mixture.
NMR samples of 200 Al were introduced in short 5-mm tubes and sealed tightly. Before data acquisition, the samples were kept a 37 jC for 1 h, for allowing equilibrium alignment to be established. Deuterium NMR spectra were recorded at 55.3 MHz on a Chemagnetics CMX 250/360 spectrometer. The standard quadruple echo sequence [46] with s = 50 As, 90j pulse of 2.1 As and a repetition time of 1.2 s was used. Four thousand scans were accumulated; 4 K data points were acquired, fractionally left-shifted to start the record at the top of the echo, baseline-corrected and zero-filled to 16 K. A line broadening of 100 Hz was applied to the free induction decay prior to Fourier transformation.
Computational methods
3D construction of the molecules
3D structure of peptides, phospholipids and piracetam was calculated as previously described [20,47 -49] . The methods account for the contribution of a lipid -water interface by the concomitant variation of the dielectric constant and the energy of transfer of atoms from a hydrophobic to a hydrophilic environment.
For the Ah Tyr-22-42 peptide, the conformation of the 22 -28 segment was calculated using the stereoalphabet procedure [50, 51] , with the 29 -42 end considered as ahelical. Briefly, in this procedure, six values of //w torsional angles (/ and w values: À 60, À 40; À 160, + 160; À 140, + 80; À 80, + 160; À 80, + 80; + 60, + 60), representing the most frequent angle pairs of the Ramachandran plot, are combined to find the most stable conformation of the whole Ah Tyr-22-42 peptide. 6 n conformations of the peptide are thus considered, with n = 7 (residues 22 to 28). The most stable structure after energy minimisation is considered for further calculations.
The molecules were then oriented at the hydrophobic/ hydrophilic interface taking into account the hydrophobic and hydrophilic centres, calculated as described elsewhere [47] .
The molecular hydrophobicity potential (MHP) of piracetam was determined as described by Brasseur [48] .
Assembly of Ab Tyr-22-42 or Ab 29 -42 with phospholipids and piracetam
The procedure is derived from that used to surround drugs with lipids [47] . In the hypermatrix procedure, the lipid/water interface is taken into account by linearly varying the dielectric constant e between 3 (above the interface) and 30 (below the interface).
In the calculations, we simulate the interaction of Ah 29 -42 or Ah Tyr-22-42 with either dipalmitoylphosphatidylethanolamine (DPPE) molecules or with a lipid molecule (DPPE) complexed to piracetam. This complex was obtained as described previously [49] .
The initial position and orientation of the molecules are defined using the TAMMO procedure [47] All calculations are performed on Pentium III processors, using the Z-TAMMO software. Graphs were drawn using Win-MGM (Ab Initio technology, Obernai, France).
Materials
Ah 29 -42 peptide was synthesised by Polypeptides laboratories (Wolfenbüttel, Germany) and solubilised in 1,1,1,3,3,3-hexafluoro-2-propanol (HFP) except for NMR measurements (cf. supra). The sequence of Ah 29 -42 is Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala. The synthesis of Ah Tyr-22-42 fragment was performed by using FMOC chemistry on a PerSeptive Biosystem solid-state peptide synthesiser. The peptide was purified by HPLC (Waters) and its identity and purity were confirmed with mass spectrometry. Piracetam provided by UCB Pharma (Brainel' Calcein, purchased from the Sigma Chemical Co., was purified by chromatography on Sephadex LH-20 following the technique of Lelkes [41] , and the purity of the final product was checked by TLC on silica gel G using CH 3 OH/NH 4 OH 28% (9:1.5 v/v) as mobile phase. 1,2-Dimyristoyl-n-glycero-3-phosphocholine (DMPC), deuterated 1,2-di[myristoyl-d 27 ]-n-glycero-3-phosphocholine (DMPC-d 54 ) and 1,2-dihexanoyl-n-glycero-3-phosphocholine (DHPC) were purchased from Avanti Polar Lipids (Alabaster, AL) and deuterium [ 2 H]-depleted water from Cambridge Isotopes (Cambridge, MA). Other reagents were obtained from E. Merck (Darmstadt, Germany) and were of analytical grade.
Results
Fluorescence and light scattering studies
Fusion of lipidic phases
The measurement of fluorescence dequenching of octadecylrhodamine B (R 18 ) is an established technique to study the fast mixing of lipids occurring during fusion of adjacent membranes [37] .
Piracetam did not induce any significant dilution of octadecylrhodamine B up to a piracetam/lipid molar ratio of 9600 during an exposure time of 25 min, suggesting no effect on mixture of lipidic phases (Fig. 1) . In contrast, with peptide Ah 29 -42, a rapid and marked increase in fluorescence was observed over the first few minutes followed by a very slow increment, as already observed for other fusion peptides [20, 52] (Fig. 1) . The effect of peptide Ah 29-42 was dose-dependent and was maximal for a peptide/ lipid molar ratio of 0.2.
This increase of fluorescence induced by peptide was almost completely prevented when liposomes are preincubated with piracetam (20 min), before the addition of peptide (Fig. 1) . This effect was concentration-dependent (increasing piracetam/peptide molar ratios from 9.6 to 960) and was not observed when piracetam was added after the incubation of liposomes with peptide.
Fusion of aqueous phases
Fusion of liposome aqueous compartments can be monitored by the decrease of HPTS fluorescence following the mixture of HPTS and DPX contained in the aqueous compartment of two separate liposome preparations.
Piracetam did not induce any significant decrease of fluorescence (up to a piracetam/lipid ratio of 9600) during an exposure time of 25 min (Fig. 2) . In contrast, Ah 29-42 induces a fast decrease of fluorescence (t 1/2 < 30 s) which was peptide/lipid ratio-dependent (from a ratio of 0.3 to 3) (Fig. 2) . The maximum effect was obtained at a peptide/lipid molar ratio of 3.
At this ratio, we investigated the effect of increasing amounts of piracetam (piracetam to peptide molar ratios from 9.6 to 960). Preincubation of piracetam, at a piracetam/ peptide ratio of 960, during 20 min before the addition of peptide prevented almost completely the mixture of the two fluorescent probes. Again, it is interesting to note the dosedependent effect and the fact that piracetam was not able to reverse the effect of the Ah-amyloid fragment when peptide was first incubated with liposomes (Fig. 2) . 
Size of the liposomes
To further verify the ability of Ah 29 -42 peptide and/or piracetam to induce fusion of membranes, we investigated their capacity to modify the apparent size and homogeneity of the liposomes preparation by means of a light scattering assay (Fig. 3) .
Piracetam had no effect on the apparent size diameter of liposomes since the size obtained was similar to that observed for control liposomes. In contrast, at a peptide/ lipid molar ratio of 2, Ah 29-42 peptide caused a striking increase in the apparent diameter of the particles and induced the appearance of two populations (Fig. 3) .
Again, preincubation of liposomes with piracetam before the addition of peptide prevented the appearance of the two populations induced by the addition of peptide. As for the other experiments, no effect of piracetam was observed when the peptide was incubated with liposomes before the addition of the drug (Fig. 3) .
Calcein permeability
Calcein is a polar molecule that has been widely used to study the permeability of lipid bilayers and has been originally described for this application by Weinstein et al. [40] .
The effect induced by Ah 29 -42 peptide, piracetam or both on membrane permeability is shown on Fig. 4 . In contrast to piracetam which did not induce any significant leakage of entrapped calcein (up to a piracetam/lipid ratio of 9600) during an exposure time of 25 min, Ah 29 -42 peptide induced a fast ( < 60 s), dose-dependent and almost complete release of calcein from liposomes as observed previously for mellitin [53] , a known porogenic agent [54] . The release was observed at peptide to lipid ratios ranging from 0.3 to 12 and was maximal from a ratio of 6.
At this peptide/lipid ratio, preincubation of piracetam with lipids prevented almost completely the release of calcein induced by the peptide in a dose-dependent fashion (piracetam/peptide ratios from 9.6 to 960). Again, piracetam was not able to reverse the effect of the Ah-amyloid fragment when the peptide was incubated with liposomes prior to the addition of piracetam (Fig. 4) . (Fig.  5A ) gave a broad spectrum characteristic of MLV with a maximum at high field and a shoulder at low field. At peptide/phospholipid ratio of 0.2, peptide-containing liposomes spectra (Fig. 5B) revealed modifications of lipid organisation depicted by a narrow signal that became very important at 65 jC. Addition of piracetam in liposome suspension (drug/ lipid ratio of 20) had no significant influence on the spectral shapes (data not shown) but incubation of liposomes with piracetam prior to the addition of the peptide to the sample markedly reduced the peptide effect as illustrated by the reduction of the narrow signal at 65 jC (Fig. 5C ) compared to what was observed for MLV incubated with peptide alone (Fig. 5B) . The Ah 29 -42 peptide effect was irreversible since adding piracetam to peptide-containing liposomes had no influence on the development of the narrow signal induced by the peptide (data not shown).
For comparing the effect of Ah 29 -42 fragment with that of peptide Ah Tyr-22-42 which was used in the 2 H NMR studies performed with DMPC/DHPC bicelles, 31 P NMR spectra of DMPC/DHPC (3:2 molar ratio) liposomes were run without and with that longer peptide. Control liposomes (Fig. 6A) revealed a small proportion of narrow peak that increased when Tyr-22-42 peptide was added to the liposomes (peptide/phospholipids ratio of 0.04) (Fig.  6B) . Since after purification of Ah Tyr-22 -42 fragment a very limited amount of peptide was obtained, all the available peptide was used for 2 H NMR measurements on bicelle samples.
3.2.2.
2 H NMR The 2 H quadruple echo spectrum of DMPC-d 54 in bicelles was run for control sample (Fig. 7A) . The deuteron spectra are characteristic of macroscopically aligned phospholipid bilayers oriented with their normal orthogonal to the magnetic field direction [43] . The 90j components of the 2 H powder pattern are the only visible components for this sample with a very high degree of orientation. The separation between the outermost lines corresponds to the quadrupolar splitting of the C 2 -C 5 methylene groups of DMPC (plateau region) while the central doublet is assigned to the deuteron resonance of the DMPC terminal methyl group [55] .
The incorporation of piracetam in bicelle solution slightly modified the 2 H NMR spectrum of DMPC-d 54 in bicelles. As seen on spectra of Fig. 7B , the resolution of spectral components is reduced compared to that observed for control bicelles. The temperature effect between 35 and 40 jC was negligibly small.
The incorporation of Ah Tyr-22-42 peptide in the bicelle preparation had dramatic effects on the spectral shape (Fig.  7C ). Already at 35 jC, the broadening of the spectral components evidenced phospholipid structural perturbation. By heating the sample up to 40 jC, a narrow peak became prominent and this transformation became more pronounced even after cooling the sample down to 35 jC. In the presence of preliminary added drug and subsequent addition of Ah Tyr-22-42 fragment (Fig. 7D) , the major spectral modification at 35 jC induced by the peptide was prevented. Raising and lowering temperature did not appreciably modify the spectral line shape.
As observed by 31 P NMR, when piracetam was added to the peptide-containing bicellar sample, the spectrum evolution was similar to that observed on sample containing only the peptide (data not shown). The transformations induced by the peptide are irreversible.
Molecular modelling
The molecular structure of piracetam is presented on Fig.  8A ; it was obtained as described elsewhere [49] . Molecular Hydrophobicity Potentials (MHP) (Fig. 8B) , based on atomic transfer energies and calculated as described by Brasseur [48] , show clearly that piracetam is perfectly amphipathic, one moiety being hydrophilic (green envelope) and the other being hydrophobic (orange envelope). This property is related to the ability of piracetam to coat the phospholipid headgroups [49] .
The interaction between the Ah Tyr-22-42 peptide and DPPE molecules was calculated using the hypermatrix procedure [47] . Fig. 9A shows clearly that the peptide induces a destabilisation of the lipids by disturbing the parallelism of the acyl chains. This is accompanied by the appearance of a negative curvature at the lipid surface. As already suggested for other tilted peptides [30] , these changes could be the first events leading to lipid fusion. In contrast, when the same peptide interacts with DPPE in the presence of piracetam, these effects are lost, i.e. no perturbation of the acyl chain organisation can be observed, as well as no change in the lipid curvature (Fig. 9B) . The same was observed when calculating the interaction of Ah 29-42 with DPPE and DPPE/piracetam complexes (data not shown).
Discussion
The development of new therapeutic approaches to the treatment of cognitive disorders is a real and urgent problem due to demographic changes and the strong increase in mean life expectancy in developed countries. Among the possible therapeutic interventions, 2-pyrrolidone derivatives [56] such as piracetam are currently used in some countries. This nootropic agent for which no metabolite has been found [57] is known to enhance the oxidative glycolysis, to increase acetylcholine release and synthesis of cytochrome h5 [58] , to improve red blood cell deformability in vitro and to restore impaired deformability of physiologically deoxygenated sickled red cells [59] . In addition, recent interest has focused on the neuroprotective effects of piracetam, for instance, in the aftermath of acute stroke [60] and on its antimyoclonic action [61] . The molecular basis of piracetam beneficial effects in Alzheimer's disease is, however, unknown.
By using biophysical techniques, NMR spectroscopy and conformational analysis, the present study was aimed at investigating the effect of piracetam on the lipid-destabilising activity induced by Ah fragments. The in vivo relevance of the experimental model employed in the current work has been ascertained by literature data. With respect to peptides, most of our experiments were carried out with Ah 29 -42 at peptide concentrations varying from 1 to 50 AM. Under normal conditions the physiological concentration of Ah in the cerebrospinal fluid is around 0.5 nM [62, 63] but by aging or under pathological situations, the degradation pathway of Ah via the low density lipoprotein receptor-related protein or via a scavenger receptor is reduced by f 45% [64] , which would increase the extracellular content of Ah. Moreover, since biological membranes are heterogeneous, locally high peptide concentrations can be obtained transiently and, thus, the peptide concentrations used could be similar to those found under in vivo conditions. Likewise, the maximum effect of piracetam was observed for drug concentrations compatible with those used in clinics (piracetam/peptide ratio of f 1000 implying a piracetam concentration of 10 mM; [65] ).
One of the most characteristic neuropathological signs of Alzheimer's disease is the deposition of neuritic plaques composed of Ah proteins, 39 -42 amino acids long, and derived from the transmembrane region of the APP [66] . Conformational analysis of the Ah protein showed that its Cterminal domain (e.g. amino acids 29 -40 or 29-42) has properties similar to those of the fusion peptide of viral proteins [67] , i.e. a tilted penetration into membranes [48, 52] . This oblique insertion is thought to be responsible for disturbance of the acyl chain parallelism, curvature of the membrane surface and, consequently, membrane destabilisation. As previously shown [20, 68] , Ah 29 -42 or its less hydrophobic analog Ah 22-42 is able to induce membrane fusion and permeabilisation of lipid vesicles mimicking the composition of neuronal membranes [35] . We have shown here that the fusogenic effect is related to the appearance of non-bilayer structures where isotropic motion occurs, as measured by 31 P NMR studies, an observation which was previously related to fusogenic properties of other peptides [69 -72] . As observed by 2 H NMR, the Ah Tyr-22 -42 fragment effect on bicelles [73, 74] is quite comparable to the 29-42 fragment perturbing effect. Ah Tyr-22-42 disorganises the bilayer structure as seen on the spectra by the transformation of the broad signal into a relatively narrow peak. Molecular modelling calculations support these experimental observations and suggest that lipid destabilisation could be due to the ability of tilted peptides to adopt metastable positions in the presence of lipids [75] . According to several observations, emerging hypotheses to explain the benefit of piracetam in Alzheimer's disease may involve lipids. First, piracetam is an amphiphilic drug and several molecules of piracetam simultaneously interact with one phospholipid molecule, as shown by molecular modeling. In the case of DPPE, we can consider that more than 80% of the water molecules in contact with the phospholipid polar heads have been replaced by piracetam, thus modifying the physical properties of the phospholipids [24, 49] . Second, using a two-hybrid system as described by Hughes et al. [76] and Festy et al. [77] , we showed no effect of piracetam on the interaction properties of the entire Ah protein. Third, in 1 H NMR, the proton chemical shifts of the drug mixed with Ah 29 -42 (2:1) obtained in organic solution did not reveal any significant modifications compared to the shifts of the drug alone in DMSO solution.
Investigating further the effect of piracetam on membrane fusion or permeability induced by Ah peptide, we have shown that piracetam is able to significantly decrease the fusogenic and destabilising effect of Ah 29-42, in a concentration-dependent manner. It is worth noting that the same is observed for Ah 29 -40 and Ah 22 -42. This is in agreement with the 31 P and 2 H NMR results since the phospholipid bilayer disorganisation induced by the two fragments and shown by the development of a narrow peak is substantially reduced in piracetam containing samples. This may be interpreted as a stabilisation of the bilayer structures that inhibits their transformation into isotropic structures responsible for the observed narrow signals as it was observed for inhibitors of viral fusion (lipogastrins [78] ). This effect only occurs when the drug is incubated with liposomes prior to peptide addition. Adding piracetam to liposomes preincubated with peptide does not reverse the effect of the peptide on the lipids, suggesting that the lipid destabilising process induced by the peptide is irreversible.
According to our observations and data reported in the literature, the benefit of piracetam in Alzheimer's disease may thus result from interactions with lipids. Two main hypotheses could explain the potential inhibitory effect of piracetam on membrane destabilisation induced by Ah 29 -42. First, piracetam could make the membrane interfaces more polar and hydrated [79] and it is well known that strongly hydrated lipids such as phosphatidylcholine inhibit the fusion of viral membranes with negatively-charged liposomes [80, 81] . Conversely, less hydrated lipids such as phosphatidylethanolamine sustain membrane destabilisation. Second, inhibition of fusion could also result from expanding the headgroup area of the outer monolayer so as to produce positive curvature strain, a process which locally curves the cell membrane in a direction opposite to that induced by the fusogenic peptide [82] .
While the peptide induces lipid disorganisation and negative curvature of the membrane interface, conformational analysis showed that piracetam, when preincubated with lipids, coats the phospholipid headgroups. Calculations suggest that this prevents the appearance of curvature. This is especially pronounced for phosphatidylethanolamine. Additionally, insertion of molecules with an inverted cone shape, such as piracetam, into the outer leaflet of one or both membranes makes the formation of these structures energetically less favourable and therefore decreases the likelihood of membrane fusion. In such a manner piracetam may hinder the permeabilising effect of Ah-peptide.
Taken together, our data indicate that piracetam inhibits the lipid-destabilising effect of the amyloid peptide, but additional knowledge on this protective effect is required to fully develop the therapeutic potential of 2-pyrrolidone derivatives.
